What Happened?
Shares of animal health company Elanco (NYSE: ELAN)
jumped 2.2% in the afternoon session after the company announced its parasite protection product, Credelio Quattro, reached $100 million in net sales in less than eight months. This achievement makes the chewable tablet Elanco's fastest pet health product to achieve blockbuster status. Launched in January, Credelio Quattro protects dogs from fleas, ticks, heartworm disease, and three types of intestinal parasites. The product has rapidly gained traction, capturing approximately 14% of the dollar share in broad-spectrum sales from U.S. veterinary clinics by June.
After the initial pop the shares cooled down to $18.93, up 2.7% from previous close.
Is now the time to buy Elanco? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Elanco’s shares are somewhat volatile and have had 14 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 5 days ago when the stock dropped 4.1% on the news that competitor Boehringer Ingelheim announced the U.S. launch of a new, advanced vaccine for swine.
The new vaccine, INGELVAC CIRCOFLEX ® AD, is the first to combine two key antigens in a single dose, potentially creating a more effective product in the animal health market. This development introduces fresh competitive pressure for Elanco, which operates in the same livestock health space, sparking investor concern over potential impacts on its market share. The stock's decline also came amid broader market weakness, as U.S. markets had closed lower the previous day on concerns about tariffs and rising bond yields, adding to the negative sentiment.
Elanco is up 57.1% since the beginning of the year, and at $18.93 per share, has set a new 52-week high. Investors who bought $1,000 worth of Elanco’s shares 5 years ago would now be looking at an investment worth $673.49.
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
